Avity Investment Management Inc. Decreases Stake in Amgen Inc. $AMGN

Avity Investment Management Inc. decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 30.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 73,373 shares of the medical research company’s stock after selling 32,766 shares during the period. Avity Investment Management Inc.’s holdings in Amgen were worth $20,706,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Evelyn Partners Investment Management LLP acquired a new stake in shares of Amgen in the second quarter worth $32,000. Howard Hughes Medical Institute acquired a new position in shares of Amgen during the 2nd quarter valued at $32,000. Cloud Capital Management LLC purchased a new stake in Amgen during the 3rd quarter worth $34,000. AXS Investments LLC purchased a new stake in Amgen during the 3rd quarter worth $42,000. Finally, Winnow Wealth LLC acquired a new stake in Amgen in the 3rd quarter valued at $47,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have commented on AMGN shares. Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. TD Cowen reiterated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Cantor Fitzgerald raised their target price on Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Rothschild & Co Redburn boosted their price target on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Finally, HSBC restated a “buy” rating and issued a $425.00 price target on shares of Amgen in a report on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $354.00.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported stronger-than-expected results and raised FY guidance, supporting fundamentals and cash flow — a key reason some investors remain constructive. MarketBeat Earnings & Guidance
• Positive Sentiment: Analysts lifted Amgen’s fair-value estimate on growing confidence in execution and the MariTide obesity program, which boosts upside expectations if clinical/exclusivity risks are managed. Yahoo: Narrative Shifting
• Positive Sentiment: Large investor interest: Ken Fisher’s firm increased its Amgen stake, a vote of confidence from a prominent institutional investor. Yahoo: Ken Fisher Doubles Position
• Neutral Sentiment: Amgen is being watched by retail and professional traders (trending coverage), which can amplify moves but doesn’t by itself change fundamentals. Zacks: Trending Stock
• Neutral Sentiment: Reported short-interest data in recent feeds appears inconsistent/zeroed out and is not signaling a clear squeeze or covering dynamic at this time.
• Neutral Sentiment: Amgen’s shares were reported to outperform many peers on a relative-basis despite the intraday decline, indicating sector/stock-specific flows rather than a company-specific collapse. MarketWatch: Outperforms Peers
• Negative Sentiment: Amgen (with peers) is reportedly joining a drug-discount initiative (TrumpRx), which could pressure pricing and margins for certain products if discounts are material. Benzinga: TrumpRx Participation
• Negative Sentiment: Analyst upgrades and MariTide optimism are tempered by exclusivity and long-term earnings debate — unresolved regulatory/IP questions could cap upside until clearer trial and exclusivity outcomes arrive. Yahoo: Exclusivity Concerns

Amgen Trading Down 1.4%

NASDAQ:AMGN opened at $361.13 on Wednesday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The business’s 50-day simple moving average is $359.26 and its 200 day simple moving average is $326.77. The stock has a market cap of $194.67 billion, a price-to-earnings ratio of 25.38, a price-to-earnings-growth ratio of 3.63 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter last year, the firm earned $5.31 EPS. Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.8%. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.